C/EBP\(\beta\) Controls Exercise-Induced Cardiac Growth and Protects against Pathological Cardiac Remodeling

Pontus Bostro¨ m,1 Nina Mann,2 Jun Wu,1 Pablo A. Quintero,2 Eva R. Plovie,3 Daniela Panákóvá,3 Rana K. Gupta,1 Chunyang Xiao,2 Calum A. MacRae,3 Anthony Rosenzweig,2,4,* and Bruce M. Spiegelman1,4,*

1Dana-Farber Cancer Institute and Harvard Medical School, 3 Blackfan Circle, CLS Building, Floor 11, Boston, MA 02115, USA
2Cardiovascular Division of the Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215, USA
3Cardiovascular Division, Brigham and Women’s Hospital, Boston, MA 02115, USA
4These authors contributed equally to this work
*Correspondence: arosenzw@bidmc.harvard.edu (A.R.), bruce_spiegelman@dfci.harvard.edu (B.M.S.)
DOI 10.1016/j.cell.2010.11.036

SUMMARY
The heart has the ability to grow in size in response to exercise, but little is known about the transcriptional mechanisms underlying physiological hypertrophy. Adult cardiomyocytes have also recently been proven to hold the potential for proliferation, a process that could be of great importance for regenerative medicine. Using a unique RT-PCR-based screen against all transcriptional components, we showed that C/EBP\(\beta\) was downregulated with exercise, whereas the expression of CITED4 was increased. Reduction of C/EBP\(\beta\) in vitro and in vivo resulted in a phenocopy of endurance exercise with cardiomyocyte hypertrophy and proliferation. This proliferation was mediated, at least in part, by the increased CITED4. Importantly, mice with reduced cardiac C/EBP\(\beta\) levels displayed substantial resistance to cardiac failure upon pressure overload. These data indicate that C/EBP\(\beta\) represses cardiomyocyte growth and proliferation in the adult mammalian heart and that reduction in C/EBP\(\beta\) is a central signal in physiologic hypertrophy and proliferation.

INTRODUCTION
Cardiac muscle adapts to increased pressure and/or volume with hypertrophy. This holds true for physiological stimuli, such as exercise, as well as for pathological provocations, including hypertension. Though the earliest stages appear quite similar at a morphological level, pathological cardiac hypertrophy leads to cardiovascular diseases such as heart failure and arrhythmia, whereas physiological hypertrophy does not. Thus, understanding the mechanistic distinction between these two types of cardiac growth has very important clinical implications. Numerous prior reports document transcription factors involved in pathological hypertrophy (Akazawa and Komuro, 2003; Frey and Olson, 2003), but relatively little is known about the molecular mechanisms controlling physiological hypertrophy.
Cardiomyocytes in adult mammals retain a limited ability to proliferate in response to specific stimuli (Bergmann et al., 2009; Bersell et al., 2009; Kajstura et al., 2010). This has potential importance because cardiomyocyte proliferation could serve as a basis for regeneration of an injured heart if it could be enhanced and harnessed. However, whether this process can be modulated through physiological interventions remains unclear. Moreover, whereas recent studies have implicated some signal transduction pathways involved in adult cardiomyocyte proliferation (Bersell et al., 2009), little is known about the detailed molecular mechanisms and particularly the transcriptional components that are decisive in this process. Furthermore, there is little data available on factors that control cardiomyocyte proliferation in the adult heart.

One of few known regulators of cardiomyocyte proliferation is Gata4, which was recently reported to mark proliferative cells during cardiac regeneration in the zebrafish (Kikuchi et al., 2010). This factor is also a well-known regulator of cardiomyocyte differentiation in adult hypertrophy, together with SRF, Nkx2.5, Tbx5, and Gata6 (Akazawa and Komuro, 2003).

Here, we studied a murine model of physiological hypertrophy induced by endurance exercise, using a method termed Quanttrx, which we recently developed for genome-wide, quantitative measurement of the expression of all transcriptional components (Gupta et al., 2010). The database underlying this method includes all known transcription factors, transcriptional coregulatory proteins, and all proteins that contain a motif that has been associated with transcriptional components, whether their function is known or not. We report here that endurance exercise effected a hypertrophic and proliferative program in cardiomyocytes, which was dependent on a reduction in the expression of the transcription factor C/EBP\(\beta\), and a linked increase in the expression of CITED4. Furthermore, mice with genetically reduced C/EBP\(\beta\) levels recapitulated many of the cardiac phenotypes seen in exercised mice. Importantly, mice with reduced C/EBP\(\beta\) were resistant to the development of cardiac dysfunction in response to pressure overload on the heart.
RESULTS

Cardiac Hypertrophy and Cardiomyocyte Proliferation Are Induced following Endurance Exercise

To study transcriptional regulators of physiological cardiac hypertrophy, a ramp swimming exercise model was used (Tanikke et al., 2008). As shown in Figure S1 (available online), mild cardiac hypertrophy was induced without alterations in the expression of pathological gene markers such as ANP and BNP. There was also a 45% increase in cardiomyocyte cell size (Figure S1) without any detectable difference in fibrosis or angiogenesis (Figure S1). Hence, we may conclude that healthy physiological cardiac hypertrophy occurred in these animals.

Further characterization revealed that expression of the cell proliferation marker PCNA was increased in the hearts from exercised mice (Figure 1A). To establish the cellular origin of the increased proliferation markers, confocal microscopy was employed in cardiac tissue stained for both the cardiomyocyte-selective protein α-actinin and the proliferation marker ki67. Robust ki67 staining was seen in 1%–5% of cardiomyocytes (Figure 1B). Importantly, there was a significant increase in cardiomyocyte ki67 staining in the exercised mice compared to the nonexercised controls, as judged from blinded analyses of histological sections using digital software. The more specific mitosis marker, phospho-Histone3 (pH3), was also elevated (Figure 1C), though the absolute number of positive cells was relatively low. Figure S1 shows pH3-positive cardiomyocytes in the different stages of mitosis. Thus, markers of both cell size and proliferation are elevated in the cardiomyocytes of mice in this model of physiological hypertrophy.

Previous studies have utilized the density of cardiomyocyte nuclei as an indicator of cardiomyocyte proliferation (Bersell et al., 2009). We could detect a small increase in nuclear density (100% and 132% in controls versus exercised mice, respectively; p = 0.07), but this did not reach statistical significance. However, it is worth noting that the observed increase in cardiomyocyte size would be expected to confound/dilute the calculated changes in nuclear density. DNA biosynthesis was therefore assayed using bromodeoxyuridine (BrdU) injections in mice undergoing this exercise protocol. We could detect double-α-actinin and BrdU-positive cardiomyocytes at a frequency of 1%–6% in exercised mice. Figure 1D shows a substantial increase in BrdU-positive cardiomyocytes in the hearts of exercised mice compared to the controls. Importantly, Z stack visualization of positive cells clearly demonstrates a distinct cardiomyocyte localization of the BrdU (Figure S1).
Finally, staining for the cytokinesis marker Aurora B kinase was used to demonstrate that the exercise protocol did indeed promote completed cardiomyocyte cell division (Figure 1E). Conversely, we could not detect any of these changes in proliferation markers in a murine model of pathological hypertrophy (data not shown). Taken together, these data strongly suggest that adult cardiomyocytes increase in both size and proliferation rate in response to this form of endurance exercise.

**C/EBPβ Is Downregulated during Physiological Hypertrophy**

To investigate the transcriptional basis of physiological cardiac hypertrophy, we utilized Quanttrx, a qPCR-based screen that we recently developed against all known and predicted transcriptional components (Gupta et al., 2010). We used cardiac samples from the mice characterized (above) together with cardiac samples from mice subjected to transaortic constriction (TAC) for 2 weeks. As shown in Figure S1, the TAC procedure induced a similar degree of hypertrophy as seen in the exercised animals but with elevation of ANP/BNP, thus indicating pathological hypertrophy. There were no signs of heart failure or other pathological changes in the mice subjected to TAC at this time point.

The Quanttrx screen identified 175 genes significantly regulated in the exercise model and 96 in the pathological (TAC) model (Table S1 and Table S2). Importantly, there was little overlap in the expression profile between the two models. In fact, there was a significant, negative correlation between the changes induced in the respective model (Figure S2; \(r = -0.32; p < 0.001\)). Thus, these models of pathological and physiological hypertrophy express distinct programs of transcriptional components.

Of the 175 transcription factors regulated by physiological hypertrophy, 47 (27%) had no known function (no PubMed annotation). However, 10 transcription factors with known functions in cardiac differentiation and/or adult hypertrophy were differentially regulated in the swim model. These included well-known genes such as Ncx2.5, Gata4, Tbx5, Mef2c, and Gata6. Furthermore, 13% of the differentially expressed factors had known or suggested roles in cellular proliferation. Less than 1% of the genes regulated in the pathological model had any known role in cellular proliferation.

Based on the magnitude of expression changes and absolute cardiac expression, we chose 30 genes out of this preliminary list of 272 and performed qPCR analyses in completely new samples of either physiological (endurance exercise) or pathological (TAC) hypertrophy. Eight out of these 30 showed robust validation (Figure S2 and Figure 2A), and these were further analyzed for cardiomyocyte-specific expression. Figure S2 shows expression of these genes in cardiomyocytes and non-cardiomyocytes after density gradient separation. Five out of eight were expressed primarily in the cardiomyocyte fraction, and these were subsequently analyzed using adenoviral-mediated forced expression and/or siRNA-mediated knockdown, using changes in cell size of rat neonatal cardiomyocytes as our endpoint. Gbx2, Cited4, Mlx, and Mefox1 failed to demonstrate any effect on cardiomyocyte sizes (Figure S2), but reduction of C/EBPβ caused a clear increase in cell size (Figure 3A).

C/EBPβ is a member of the bHLH gene family of DNA-binding transcription factors and has known roles in cell proliferation and differentiation in other tissues (Sebastian and Johnson, 2006), including adipose cells and liver. However, it has not been studied in the context of the cardiomyocyte. C/EBPβ mRNA expression was reduced by 61% in hearts in the exercise model when assayed in new samples, but this effect was not observed in a model of pathological hypertrophy using transverse banding (TAC) performed in parallel (Figure 2A). Downregulation of C/EBPβ was also seen in response to the exercise training at the protein level (Figure 2B). Expression of the short LIP C/EBPβ isoform that is inhibitory toward C/EBPβ function was undetectable in these cardiac samples (Figure 2B). Confocal microscopy illustrated that it was indeed cardiomyocyte-specific expression of C/EBPβ that was reduced with exercise (Figure 2C). Consistent with this, C/EBPβ expression was enriched in the cardiomyocyte fraction, versus noncardiomyocyte cells, following gradient purification of rat neonatal cardiomyocytes (Figure 2D and Figure S2).

Two additional mouse models of exercise were tested for effects on C/EBPβ expression: acute and low-intensity treadmill running. Neither treatment resulted in cardiac hypertrophy (data not shown), but reduction of C/EBPβ expression occurred in the acute setting (40 min of treadmill running), as seen in Figure 2E. Thus, C/EBPβ expression is reduced relatively early in endurance exercise.

**Reduction in C/EBPβ Expression Induces Hypertrophy and Proliferation in Cultured Cardiomyocytes**

The functional consequences of experimental reduction of C/EBPβ were assessed in detail in primary rat cardiomyocytes. An siRNA was used to reduce C/EBPβ levels to approximately the levels of mRNA observed after endurance exercise (43%) (Figure S3). As demonstrated in Figures 3A and 3B, the forced decrease in C/EBPβ mRNA was sufficient to drive an increase in cell size and in the rate of protein biosynthesis. No statistically significant change in cell size or protein biosynthesis was seen with forced C/EBPβ expression (\(p = 0.42\) and \(p = 0.054\), respectively). The reduction of C/EBPβ expression was also sufficient to ablate the increase in ANP levels seen with pathological provocation (Figure S3).

Interestingly, the C/EBPβ reduction via siRNA also led to an increase in cell number (Figure 3C). This was accompanied by increased PCNA expression and increased BrdU incorporation into DNA, highly suggestive of cardiomyocyte proliferation (Figures 3D and 3E). These data indicate that a reduction in C/EBPβ expression is sufficient to induce hypertrophy and proliferation in cultured cardiomyocytes.

**C/EBPβ Regulates Expression of a Gene Set Characteristic of Physiological Hypertrophy by Sequestering Serum Response Factor**

The initial Quanttrx screen revealed a specific set of regulated genes with known functions in cardiomyocyte differentiation and hypertrophy (Figure 4A and Table S1). Examples of such genes were Gata4, Tbx5, and Nkx2.5, which all induce hypertrophy (Akazawa and Komuro, 2003). Beyond these 11 genes, we also investigated expression levels of the genes that are well known to be altered in cardiac hypertrophy or differentiation, including α-MHC, TnI, and TnT, which were all upregulated in the
hearts of exercised mice (Figure 4A). The transcriptional coregulator PGC-1α has previously been demonstrated to have an important role in preventing cardiac dysfunction after the development of hypertrophy (Arany et al., 2006), and exercised mice indeed displayed increased cardiac expression levels of PGC-1α together with its downstream targets VEGF, Ndufs1, Ndufv2, and ATP5o (Figure 4A). Thus, by combining the Quanttrx screen hits with markers of hypertrophy and the PGC-1α, as well as its downstream targets, we defined an exercise-induced gene set of 19 genes (Figure 4A). The changes in mRNA expression for Nkx2.5, Tbx5, Mef2c, Gata4, and PGC-1α following TAC surgery are shown in Figure S4.

As shown in Figure 4B, reduction in C/EBPβ levels in primary cardiomyocytes resulted in a strikingly similar expression pattern. In fact, 11/19 of these genes were regulated in the same manner as in the exercise model (p < 0.001 using chi-square statistics). Furthermore, adenoviral expression of C/EBPβ induced essentially the reverse expression pattern (Figure S4). These data strongly suggest that C/EBPβ acts upstream of other transcriptional components that are also regulated in physiological hypertrophy. Especially interesting was the C/EBPβ-dependent regulation of Gata4, which has recently been demonstrated to play a major role in zebrafish cardiomyocyte proliferation during myocardial regeneration (Kikuchi et al., 2010).

Many of the genes regulated by both endurance exercise and the siRNA-mediated C/EBPβ reduction are known to be transcriptional targets of the transcription factor SRF, with SRE elements in their promoters (Akazawa and Komuro, 2003). C/EBPβ has been demonstrated to physically interact with SRF (Hanlon and Sealy, 1999), but the functional consequences of this interaction are not clear, especially in cardiomyocytes in which the role of C/EBPβ is unknown. Previous reports on the C/EBPβ-SRF interaction have suggested a positive effect on SRE-dependent elements, but the increased expression levels of Gata4 and α-MHC (Figure 4A) following C/EBPβ siRNA here suggested a negative regulation of SRE-dependent genes in cardiomyocytes.

A physical interaction between the SRF and C/EBPβ proteins was indeed observed using coimmunoprecipitation from primary cardiomyocytes (Figure 4C). Next, chromatin immunoprecipitation (ChIP) assays were performed, examining the binding of SRF to the Gata4 and α-MHC promoters following gain and loss of the C/EBPβ protein. As shown in Figure 4D, CEBPβ reduction using siRNA dramatically increased SRF binding to the promoters of both α-MHC and Gata4, in which SRF is known to play a positive regulatory role. Conversely, adenoviral expression of C/EBPβ reduced SRF binding to these promoters. Thus, C/EBPβ interferes with SRF binding to the promoters of critical cardiac genes (Figure 4E).
The recent discovery of the ErbB4 pathway in cardiomyocyte proliferation led us to investigate whether C/EBPβ could be affected by such signaling. This was especially interesting as ErbB4 signals via AKT1, a kinase known to function in physiological hypertrophy (DeBosch et al., 2006). We thus investigated the connection of this pathway to C/EBPβ using both forced expression of wild-type AKT1 and a dominant-negative AKT1 (Nagoshi et al., 2005). As demonstrated in Figure S4, increasing AKT1 activity did indeed reduce C/EBPβ expression levels together with an expression profile resembling what was observed with exercise with increased expression of Tbx5, Gata4, TnI, and α-MHC. Conversely, the dominant-negative AKT1 mutant increased C/EBPβ in parallel with decreased mRNA levels of Tbx5, Gata4, TnI, and α-MHC. We could thus conclude that AKT1 activity evokes the same gene expression profile as seen in exercise. We next used C/EBPβ adenovirus together with AKT1 overexpression to establish whether C/EBPβ indeed act downstream on AKT1 in the regulation of these target genes. As demonstrated in Figure S4, C/EBPβ overexpression ablated the positive expression effects of AKT1 on Tbx5, Gata4, TnI, and α-MHC. Taken together, these data suggest that AKT1 regulates C/EBPβ expression, connecting C/EBPβ to a previously characterized physiological growth pathway in the heart.

C/EBPβ Negatively Regulates CITED4, a Transcription Factor Promoting Cardiomyocyte Proliferation

The SRF-dependent gene set described above includes well-known regulators of cardiomyocyte hypertrophy, but apart from Gata4, they are not known to participate in a proliferative phenotype, such as we see with C/EBPβ reduction. We thus analyzed the list of exercise-induced cardiac genes (Figure S2) for those controlled by C/EBPβ that might influence or control cardiomyocyte proliferation. Preliminary studies using gain and loss of function for six factors apparently downstream of CEBPβ led us to focus on CBP/p300-interacting transactivator with ED-rich carboxy-terminal domain 4 (CITED4). Indeed, CITED4 showed a robust increase in exercised hearts (Figure 5A), and its expression level was markedly altered with C/EBPβ gain or loss of function in vitro (Figure 5B).

Strikingly, forced CITED4 expression (Figure S5) increased cardiomyocyte cell numbers together with an increased percentage of ki67-positive cells (Figures 5C and 5D). Conversely, siRNA directed against CITED4 (Figure S5C) reduced both cell numbers and ki67 staining (Figures 5C and 5D). Gene expression analysis also revealed a gene set of
proliferative genes increased in endurance exercise (Figure S5), in which the important cell cycle/proliferation factors CyclinD1 and n-myc also displayed increased expression with forced CITED4 expression together with SRF (Figure S5).

To investigate the functional relationship between C/EBPβ and CITED4, we used siRNA directed against CITED4 together with C/EBPβ siRNA. As shown in Figure S5, CITED4 knockdown could completely abolish the effect of cellular proliferation seen with the C/EBPβ reduction. Thus, C/EBPβ is likely to mediate its antiproliferative effects, at least in part, via CITED4 expression.

**C/EBPβ Controls Cardiomyocyte Proliferation in the Zebrafish Embryo**

We next tested the role of C/EBPβ reduction in zebrafish, a simple and experimentally accessible in vivo system. Anti-C/EBPβ morpholino oligonucleotides were injected into zebrafish embryos transgenic for cmlc2-GFP at the one-cell stage (Figure 6A). Figure 6B shows zebrafish hearts dissected at 36 hr and stained for nuclei (DAPI, blue) and plasma membrane (integrin, red). Quantification of these images revealed increased cardiomyocyte cell number but did not change cardiomyocyte size up to 72 hr postfertilization (Figure 6D). Furthermore, 20 min BrdU labeling of 48 hr hpf embryos demonstrated increased DNA synthesis (Figure 6C and quantification in Figure 6E). Of note, Gata4 mRNA expression was significantly increased, consistent with results shown above (Figure 6F). Thus, reduction of C/EBPβ induces cardiomyocyte proliferation in zebrafish hearts in vivo.

**Heterozygosity for C/EBPβ in Mice Mimics Cellular Aspects of Endurance Exercise and Is Cardioprotective against Pressure Overload**

Mice with a complete loss of C/EBPβ show pre- and perinatal lethality, but heterozygotes are relatively normal. Mice heterozygous for C/EBPβ have cardiac C/EBPβ mRNA levels reduced to a similar level as observed in exercised mice (50% reduction) (Figure S6). These heterozygous animals were therefore used to study the role of this factor in mammalian cardiac function. The exercise-induced gene set defined above was analyzed in hearts of the C/EBPβ+/C0 compared to wild-type littermates, and a pattern of expression changes similar to that seen with exercise was seen for multiple genes (8 of 19 genes) (Figure S6). Furthermore, measurements of cell size (done in a blinded manner) revealed cardiomyocyte hypertrophy (Figure 7A) and an increase in heart weight (Figure S6). Echocardiographic studies revealed a small but significant increase in fractional shortening, an important parameter of improved heart function (Table S3). No differences in heart wall thickness were observed.

Cardiomyocyte proliferation was also assayed at baseline in the C/EBPβ+/ mice. Notably, there was a clear increase in
mice and littermate controls, incubated them in culture with BrdU for 48 hr, and stained for proliferation markers. Fewer than 0.05% ± 0.1% of cardiomyocytes from control mice were BrdU positive. However, cells from the C/EBPβ+/− mice displayed a 10-fold increase in positive nuclear staining (0.6% ± 0.2% of cells; p < 0.05 compared to control) (Figure 7E).

We next performed the exercise protocol on the C/EBPβ+/− mice together with littermate controls. As shown in Figure S7, there was no further reduction in C/EBPβ levels with exercise in the C/EBPβ+/− mice compared to wild-types. In addition, we could only detect a minor increase in heart mass in the exercised C/EBPβ+/− mice (Figure S7). More interestingly, however, the C/EBPβ+/− mice displayed a clear increase in exercise capacity at baseline (Figure S7), suggestive of a functional consequence of C/EBPβ reduction in vivo.

To critically assess the possible protective role of the cardiac changes seen in the C/EBPβ+/− mice, we performed transverse aortic constriction (TAC) to induce pressure overload on the heart leading to pathological cardiac hypertrophy and dysfunction in mice. As expected, TAC resulted in progressive reduction in cardiac function, as judged by fractional shortening (FS) in the wild-type mice. However, the C/EBPβ heterozygous mice displayed only a minor reduction in contractile function after TAC (Figure 7F). Pulmonary edema is a very important characteristic of cardiac failure in both mice and humans, and the differences in heart function between the two groups were also supported by a significant difference in lung weight (Figure 7G). Ventricular dilatation (as a marker of cardiac failure) also increased more rapidly in the wild-type mice than in the C/EBPβ+/− animals (Figure S7).

According to our IACUC rules, mice subjected to TAC had to be sacrificed when cardiac function (fractional shortening) decreased by at least four standard deviations from the mean, as this represents a very substantial deterioration likely to be associated with heart failure. Using such criteria, Kaplan-Meier analysis demonstrated that wild-type littermates were significantly more likely to develop this degree of cardiac dysfunction after TAC than C/EBPβ+/− littermates (Figure 7H). Thus, the reduction in C/EBPβ expression in the hearts of heterozygous mice, quantitatively comparable to that seen after exercise training, results in improved cardiac function and resistance to a heart-specific pathological stress.

**DISCUSSION**

Despite the well-documented beneficial cardiovascular effects of exercise, our understanding of the mechanisms underlying these benefits, particularly in the heart, remains very limited. In particular, little is known about the transcriptional pathways underlying physiological hypertrophy, as compared to the wide variety of transcription factors implicated in pathological hypertrophy. Here, we provide evidence for a cardiac pathway induced by exercise and mediated by the reduction of C/EBPβ, resulting in physiological hypertrophy. Interestingly, exercise or experimental decreases in C/EBPβ expression induce increases in both cardiomyocyte size and cell division, which are likely to contribute to some of the benefits observed. Moreover, these effects were tightly coupled to a beneficial

---

**Figure 5. CITED4 Is Upregulated with Endurance Exercise, Regulated by C/EBPβ, and Its Forced Expression Induced Cardiomyocyte Proliferation In Vitro**

(A) mRNA levels of cardiac CITED4 in control and endurance-exercised (swim) mice normalized to 18S expression.

(B) mRNA expression of CITED4 in primary rat neonatal cardiomyocytes after siRNA knockdown (left) or adenoviral overexpression (right) of CITED4. Expression levels are normalized to 18S.

(C and D) Rat neonatal cardiomyocytes treated with either an adenovirus overexpressing CITED4 (left) or a siRNA directed against CITED4 (right). Cells were then stained against α-actinin and ki67, and positive cells were counted in 20× view fields from 15 random images per group.

(E) Rat neonatal cardiomyocytes treated with control siRNA, C/EBPβ siRNA, or C/EBPβ siRNA + control siRNA, C/EBPβ siRNA + Cited4 siRNA, followed by assay of BrdU incorporation as previously described. Data is pooled from three experiments and presented as percent of control.

Error bars represent standard error of mean. *p < 0.05 versus respective control, and † versus C/EBPβ siRNA using one-way ANOVA statistics. T test was used for (A–D). See also Figure S5.

cardiomyocyte nuclear density (Figure 7B), consistent with increased expression of proliferation markers in the cardiomyocytes that was also observed (Figure S6). BrdU injections resulted in an increased number of positive cardiomyocytes in the C/EBPβ+/− mice (Figure 7C and Figure S6). We also detected Aurora B kinase-positive cardiomyocytes in C/EBPβ+/− cardiac tissue (Figure 7D). To study adult cardiomyocyte proliferation directly, we also isolated adult cardiomyocytes from C/EBPβ+/−.
metabolic gene set, including an induction of the PGC1α pathway. Lastly, we observe that reduction in C/EBPβ expression was itself sufficient to result in improved cardiac function and resistance to pathological/lethality induced in the heart by pressure overload.

Considerable attention has recently been focused on the potential for cardiomyocytes to proliferate, illustrated in several recent papers (Bergmann et al., 2009; Bersell et al., 2009; Kajstura et al., 2010). In fact, the proliferative behavior observed here in cardiomyocytes caused by the endurance exercise was quantitatively similar to that seen with NRG1 treatment previously (Bersell et al., 2009). Data presented here also suggest that C/EBPβ is an important functional target of ErbB4-related signaling pathways, particularly AKT1, in cardiomyocytes.

Exercise and genetic reduction of C/EBPβ both resulted in the induction of a specific gene set in vitro and in vivo that is known to influence cardiac function. Tbx5, Nkx2.5, Gata4, and α-MHC have all been demonstrated to induce hypertrophy in adult cardiomyocytes (Akazawa and Komuro, 2003). It is thus likely that C/EBPβ exerts part of its hypertrophic actions via increases in this important gene set. It is also worth noting that these effects of reduced C/EBPβ expression do not require massive changes in mRNA or protein levels; 50%–60% changes through exercise or genetic alterations are sufficient to bring about rather profound changes in cardiomyocyte biology and the in vivo response to biomechanical stress. This strongly suggests a rheostat-like role for C/EBPβ, whereby small but highly regulated changes in this factor are reflected in a broad downstream response in the heart.

Among affected genes was also PGC1α, a transcriptional coactivator that is important for mitochondrial biogenesis and protection against pathological heart stress (Arany et al., 2006; Finck and Kelly, 2007). As gain-of-function studies in vitro did not suggest that PGC1α induces cardiomyocyte hypertrophy, it is more likely that PGC1α acts via increased mitochondrial gene expression and function.

A key mechanism by which C/EBPβ controls Gata4 expression is through binding to SRF and sequestering this factor from direct binding to the Gata4 (and α-MHC) promoters. This mechanism of action may have rather broad implications for cardiac biology considering the available data on the crucial role of SRF in cardiomyocyte differentiation and the regulation of expression of Tbx5, Gata, and Nkx2.5 (Akazawa and Komuro, 2003; Chai and Tarnawski, 2002). In fact, ablation of SRF is the only known genetic knockout model that completely abolishes cardiomyocyte differentiation (Fukushige et al., 2006). Possible cardioprotective effects of C/EBPβ reduction are also consistent with recent reports that have described increased C/EBPβ DNA binding in pathological models for negative cardiac remodeling (Oh et al., 2010).
CITED4 was originally cloned 8 years ago (Bragança et al., 2002; Yahata et al., 2002), but very little is known about its function. We demonstrate here that CITED4 is expressed in the heart, and its expression is increased with exercise. CITED4 levels are negatively regulated by C/EBPb expression, whereas experimental alterations of CITED4 levels in primary cardiomyocytes

Figure 7. C/EBPb+/- Mice Have Cardiac Hypertrophy and Increased Proliferation Markers and Are Resistant to Pressure Overload
(A) Cardiomyocyte size was measured in cardiac tissue from wild-type (n = 5) and C/EBPb+/- (n = 7) mice using WGA membrane staining.
(B and C) Quantification of nuclear density assayed (B) and BrdU incorporation (C) from indicated mice.
(D) Typical image of Aurora B kinase (green) positive cardiomyocyte from C/EBPb+/- mouse heart, counterstained with anti-α-actinin (red) and dapi (blue).
(E) Immunohistochemistry against phosphohistone H3 (green) in primary cardiomyocyte from an adult C/EBPb+/- mouse heart counterstained with α-actinin (red) and dapi (blue).
(F) Wild-type and C/EBPb+/- (n = 6 and 7) mice subjected to TAC and assayed for fractional shortening at indicated times.
(G) Lung weight 52 days after TAC intervention.
(H) Kaplan-Meier plot of cardiac failure-free fraction at indicated times in wild-type and C/EBPb+/- mice following TAC procedure. Error bars represent standard error of mean. *p < 0.05 versus respective control using Student’s t test. **p < 0.01. See also Figure S7.
regulate proliferation. Forced expression of CITED4 also increased levels of cyclin D1, which is known to drive cardiomyocyte proliferation (Campa et al., 2008). Thus, it is highly plausible that C/EBPβ exerts its antiproliferative actions via inhibition of CITED4 expression. However, we cannot exclude the possibility that other pathways might also contribute.

C/EBPβ reduction in the zebrafish embryo induced significant proliferation that, together with data provided from mice, suggests an evolutionarily conserved pathway in cardiomyocytes. There was no effect on cardiomyocyte size in the fish embryos; this could reflect a species difference or could be explained by the particular developmental stage at which the oligonucleotides were utilized.

The C/EBPβ heterozygous mouse closely phenocopied the endurance exercise model, as judged from cardiac hypertrophy, cardiomyocyte proliferation, and expression of key genes of cardiac function. In fact, 42% of the gene set analyzed was regulated in the same manner by both of these perturbations in vivo. The magnitude of the effect on hypertrophy at baseline, however, was smaller than in the exercised mice, suggesting that additional pathways are likely to contribute to the changes induced in physiological hypertrophy.

Although exercise has well-known positive health effects, possible benefits of physiological cardiac hypertrophy remain unclear (such as improved outcome following pathological provocations) in either mice or man. However, we were able to demonstrate that hearts in C/EBPβ heterozygous mice had improved tolerance to pressure overload. This included resistance to deterioration in cardiac function (fractional shortening) after transverse constriction and improved survival. These data are also important because transverse constriction is a very selective stress to the heart and thus would not be confounded by systemic effects of reduced C/EBPβ in the total body heterozygotes. Mechanistically, the increase in cardiomyocyte proliferation could possibly contribute to the functional resistance to cardiac dysfunction; such an effect would be in accordance with resistance to injury connected to proliferation observed in other systems (Bersell et al., 2009). However, improved cellular energetics (via increased PGC1α expression), physiological cellular hypertrophy, or other functional alterations could also be important contributing factors. Better understanding of the pathways affecting C/EBPβ protein expression, or drugs that suppress C/EBPβ expression in the heart, could be of significant clinical value in cardiac pathological states.

### EXPERIMENTAL PROCEDURES

#### Material

A list of utilized primers is presented in Table S2. Antibodies against PCNA, tubulin, C/EBPβ, actin, CITED4, ki67, phospho-Histone 3, Aurora B, BrDU, β-tubulin, α-actin, and nonimmune IgG were from Abcam. Antibodies to SRF and C/EBPβ were from Santa Cruz Biotechnology. HRP-conjugated secondary antibodies were from Jackson ImmunoResearch Laboratories. Alexa Fluor (488 and 633) conjugated antibodies were from Invitrogen. Pre-coated plates were from BD bioscience. Chamber slides for microscopy were from Nalge Nunc International. BioPix IQ 2.0 were obtained from BioPix AB (Gothenburg, Sweden). 35S-Methionine was purchased from Perkin Elmer were from Nalge Nunc International. BioPix iQ 2.0 were obtained from BioPix AB (Gothenburg, Sweden). 35S-Methionine was purchased from Perkin Elmer were from Nalge Nunc International. BioPix iQ 2.0 were obtained from BioPix AB (Gothenburg, Sweden).

#### Confocal Microscopy and Image Quantification

Samples were visualized using a Leica SP5 confocal microscope at 40x magnification using standard procedure. All imaging was performed with group identity blinded whereby at least 20 random images were obtained from each slide or group. Images were then quantified in BioPix IQ 2.0 in Prolong Gold with DAPI (Invitrogen).
accordance with manufacturer’s instructions (Bostrom et al., 2007; Hultén et al., 2010).

BrdU Injections and Subsequent Staining Procedure
BrdU was injected intraperitoneally 3 days prior to the end of the swim protocol at 50 mg/kg. Cardiac sections were obtained as described above, and prior to staining, the slices were incubated in 1 M HCl for 10 min on ice, followed by 2 M HCl for 10 min room temperature and 20 min in 37 degrees. Slides were then washed with 0.1 M Borate buffer 10 min and rinsed in PBS. Thereafter, the previously described protocol for immunohistochemistry was utilized.

SUPPLEMENTAL INFORMATION
Supplemental Information includes seven figures and four tables and can be found with this article online at doi:10.1016/j.cell.2010.11.036.

REFERENCES
protein/p300-interacting transactivator with ED-rich tail (CITED) 4, a new member of the CITED family, functions as a co-activator for transcription factor AP-2. J. Biol. Chem. 277, 8559–8565.


